Psychiatric disorders impose tremendous economic burden on society and are leading
causes of disability worldwide. However, only limited drugs are available for psychiatric …

Discovering drugs that efficiently treat brain diseases has been challenging. Genetic
variants that modulate the expression of potential drug targets can be utilized to assess the …

Psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder,
attention-deficit/hyperactivity disorder and autism spectrum disorder are common and result …

Using successful genome-wide association results in psychiatry for drug repurposing is an
ongoing challenge. Databases collecting drug targets and gene annotations are growing …

Realizing the promise of precision medicine in psychiatry is a laudable and beneficial
endeavor, since it should markedly reduce morbidity and mortality and, in effect, alleviate the …

Genome-wide association studies (GWAS) provide biological insights into disease onset
and progression and have potential to produce clinically useful biomarkers. A growing body …

Neuropsychiatric disorders, such as autism spectrum disorder (ASD), attention deficit
hyperactivity disorder (ADHD), schizophrenia (SCZ), bipolar disorder (BIP), and major …

The primary aim of precision medicine is to tailor healthcare more closely to the needs of
individual patients. This requires progress in two areas: the development of more precise …

Background Recent genome-wide association studies (GWASs) have revealed the
polygenic nature of psychiatric disorders and discovered a few of single-nucleotide …

We outline an ambitious project to characterize the genetic and epigenetic regulation of
multiple facets of transcription in distinct brain regions across the human lifespan in samples …